The Geography of Access: Why the Right Network Is Everything — and Why Most Researchers Have the Wrong One

A robotics engineer at a Ukrainian university had, by 2019, developed a computer vision platform for industrial quality control that benchmarked favorably against commercial systems costing three to four times as much to deploy. The technology was real, the validation was solid, and the timing — ahead of a wave of nearshoring interest that would dramatically expand European appetite for flexible industrial automation — was, in retrospect, almost perfect. What she did not have was a contact at a single European industrial investor, a relationship with any of the deep-tech funds active in the CEE region, or knowledge of which Israeli defense-to-civilian technology transfer programs might have offered a natural commercialization bridge for vision-based systems. She knew the names of these organizations from public databases. She did not know anyone who knew anyone inside them. Her emails were not answered. Her applications to two accelerator programs were rejected at the screening stage. The platform was eventually absorbed into a larger software project at her institution, where it continues to function as an internal tool. Its commercial life never began.

Her story is, in the geography of European and post-Soviet scientific commercialization, entirely ordinary. The gap between having a commercially viable technology and reaching the investors, partners, and distribution networks capable of taking it forward is not, in this landscape, primarily a gap of quality or preparation. It is a gap of connection — of warm introductions not made, of regional networks not entered, of the specific, trust-mediated access that determines whether a pitch meeting happens at all. In a world where the first filter for most investor meetings is whether someone the investor trusts has referred the founder, the researcher without a network is not competing at a disadvantage. They are, in most cases, not competing at all.

The network's centrality to commercialization is not a new observation, but its specific geography has become more complex and more consequential over the past two decades. The expansion of the European Union and its research funding infrastructure through the 2000s and 2010s created new pathways for scientific collaboration across borders — Horizon programs, EUREKA networks, bilateral science agreements — that gave researchers from Central and Eastern Europe, the former Soviet states, and non-EU innovation hubs like Israel genuine access to European research communities. What these programs did not reliably create was access to the commercial networks that run alongside and largely separate from the academic ones.

The commercial deep-tech investment ecosystem in Europe remains, despite two decades of integration rhetoric, substantially fragmented along national and regional lines. A Berlin-based deep-tech fund has relationships, deal flow, and due diligence capacity that is dense in the DACH region and attenuates rapidly toward Warsaw, Tallinn, or Kyiv. A Tel Aviv-based fund with a European mandate maintains its strongest networks in the countries where its partners have previously operated and where its portfolio companies have sought co-investors. An Amsterdam family office with a life sciences focus knows the Dutch university spinout ecosystem intimately and the Romanian or Uzbek one barely at all. The capital exists across the continent. The trust networks that direct it are local, personal, and slow to extend to researchers who have not yet established themselves within them.

Israel occupies a particular and instructive position in this landscape. The Israeli innovation ecosystem — built over decades on the foundations of military technology transfer, a dense culture of serial entrepreneurship, and a university commercialization infrastructure that has few peers globally — has produced a distinctive approach to cross-border commercialization that researchers from other regions frequently encounter as both inspiring and inaccessible. Israeli deep-tech founders entering European markets do so with established network bridges: the alumni of military technology units who have seeded the country's startup culture, the diaspora investor networks that connect Tel Aviv with London, Amsterdam, and Munich, and the specific trust relationships that decades of bilateral research collaboration have built. These bridges exist because they were deliberately constructed, over time, by institutions and individuals who understood that technology does not cross borders — relationships do.

For researchers in the CIS region — Ukraine, Georgia, Kazakhstan, Armenia, and the other former Soviet states that have produced exceptional scientific talent under conditions of chronic institutional underinvestment — the network deficit is compounded by a specific historical legacy. The Soviet scientific system, for all its dysfunction, was extraordinarily effective at training researchers across a vast range of disciplines: mathematics, physics, materials science, aerospace engineering, biochemistry. What it did not produce, because it had no use for it, was the commercial network infrastructure that translates scientific capability into market-facing ventures. The researchers who emerged from this system in the 1990s and 2000s inherited world-class technical formation and almost no exposure to the investor relationships, the entrepreneurial peer communities, or the cross-border commercial norms that their Western European and Israeli counterparts were developing simultaneously. That inheritance gap has never been fully closed, and the researchers who carry it into commercialization attempts today encounter its consequences at every stage of the process.

The mechanisms by which network gaps compound are specific and self-reinforcing. The researcher without connections to European or Israeli investor communities does not merely miss individual introductions. They miss the ambient intelligence that flows through those communities: the knowledge of which funds are currently active in their sector, which accelerator programs are genuinely valuable versus credentialling exercises, which industry partners are serious about university licensing versus using academic relationships for competitive intelligence, and which regulatory or market developments are shifting the investment appetite in ways that change what should be pitched and to whom. This intelligence is not published. It circulates through relationship networks in the form of conversation, and the researcher outside those networks receives it, if at all, months or years after it would have been actionable.

The compounding effect operates across time. Networks in the commercialization ecosystem are built through repeated interaction — the conference where a researcher meets a fund associate and follows up, the accelerator cohort where relationships form with co-founders who later make introductions, the advisory board position that places a researcher in the trust network of an investor who later leads a round. Each of these interactions is available primarily to researchers who are already embedded in the ecosystem at some level. The researcher approaching commercial networks for the first time, from outside the geography where those networks are dense, does not encounter a level playing field. They encounter a system whose entry points are largely invisible to those who have not already partially entered it.

The geographic dimension also interacts with the cultural one in ways that are rarely acknowledged in generalist commercialization advice. The norms of investor communication in Germany differ meaningfully from those in France, in Israel, and in the UK — in the expected formality of initial contact, the role of written materials versus face-to-face relationship building, the acceptable degree of ambition in a pitch, and the weight given to institutional affiliation versus individual track record. A researcher from Kyiv or Almaty approaching a Tel Aviv fund, a Munich family office, and a London deep-tech investor in the same week is not merely managing three different time zones and three different pitch decks. They are navigating three substantially different commercial cultures, each with its own unwritten expectations about how a serious founder presents and behaves.

What opens doors in this landscape is not, primarily, a better pitch deck or a more polished website — though both matter. It is the credible, trusted introduction that converts a cold name into a warm meeting. And the most reliable source of such introductions is an intermediary who already inhabits the relevant networks: who has placed companies in front of these investors before, who is known to the gatekeepers as someone whose referrals are worth taking seriously, and who understands the specific norms, expectations, and current priorities of each regional ecosystem well enough to position a researcher's technology in the terms that each audience will recognize as relevant to them.

This is what regional network access through an agency with established cases and connections provides — not a list of contacts, which any researcher can assemble from public databases, but the trust relationships that make those contacts meaningful. A warm introduction from someone the investor already knows and respects compresses months of relationship-building into a single email. A referral that comes with a track record signals to the investor that the intermediary's judgment has been validated by prior outcomes and is worth acting on. And a partner who understands the commercial culture of Europe, Israel, and the CIS simultaneously can navigate a researcher's technology through ecosystems that would otherwise require years of immersion to enter independently.

The technology does not travel on its own merits across borders. It travels on relationships — on the accumulated trust between people who have worked together, backed winners together, and built the mutual confidence that makes the next introduction possible. For the researcher in Tbilisi, Warsaw, or Kharkiv whose work is ready for the world and whose network ends at the edges of their academic discipline, this infrastructure is not a convenience. It is the precondition for everything else the series has discussed — the pitches, the preparation, the market validation, the investor negotiation — to have any prospect of reaching the right room. The door exists. The question is who already has the key.